Leukocyte adhesion defi ciency (LAD) is a recently recognized autosomal recessive trait characterized by recurrent bacterial infections, impaired pus formation and wound healing, and abnormalities in a wide spectrum of adherence-dependent functions of granulocytes, monocytes, and lymphoid cells. Features of this disease are attributable to defi ciency (or absence) of cell surface expression of a family of functionally and structurally related glycoproteins. These include Mac-l (complement receptor type 3), lym phocyte function-associated antigen-l (LF A-I), and p 150,95. Defective biosynthesis of the p chain shared by each molecule (comprised of iY.IPI complexes) represents the fundamental molecular basis of this disease. Recognition of the molecular pathogenesis of this disorder has allowed rich insights into the role of cellular adherence reactions in infl ammation and host defense.
Introduction
A family of three glycoproteins with identical f3 subunits of Mr = 95,000 has recently been defi ned on leukocyte cell surfaces (1). Each glycoprotein has a different ex subunit of Mr = 150,000 to 180,000 associated with the f3 subunit in an exf3 complex. These glycoproteins function in cell adhesion, as shown by the ability of specific monoclonal antibodies (MAbs) to inhibit a wide variety of granulocyte, monocyte, and lymphocyte cell-substrate and cell-cell interactions. Soon after this family of leukocyte adhesion glycoprotcins had been defi ned with MAb, its inherited deficiency was found in a number of patients with recurring bacterial infections and persistent granulocytosis (2-41) ( Table 1 ). This fi nding served to group these patients under a single clinical entity and at the same time provided a molecular basis for their clinical symptoms. Furthermore, studies on the leukocytes from these patients had already demonstrated a number of striking deficiencies in adhesion and adhesion-dependent functions that appear to underlie a failure to accumulate at inflammatory sites. Together with studies of MAbs on normal cells, studies on the patient model have yielded rich insights into the regulation and molecular basis of leukocyte adhesion. 38,9,12,13,9
Crowley et al 1980 (12-14) 9
Amaout et al 1982 (13, (15) (16) (17) (18) 
\0
Bowen et al1982 (19) (20) (21) 2 1 9,9
Fischer et al 1983 (22) (23) (24) (25) Beginning in 1979, a group of patients were recognized who had wide spread bacterial infections, defective neutrophil mobility, and delayed separation of the umbilical cord (5, 22, 37, 38, 40) . Other patients with recurring bacterial infections were reported who had defects in initiation of the neutrophil respiratory burst to particulate but not to soluble stimuli (29) , defects in neutrophil chemotaxis and phagocytosis (6, 41), or both (39) . One of the earliest reported patients with abnormal neutrophil phago cytosis and motility was found to have actin dysfunction (35) but later evaluation suggests adhesion protein deficiency (36) . Crowley et al (12) were the fi rst to propose that the defects in neutrophil chemotaxis and phagocytosis were secondary to an abnormality in adhesion. Their patient's neutrophils adhered weakly and failed to spread on plastic petri dishes; they also lacked a cell surface protein of 110,000 Mr. Subsequently, Arnaout et al (15) and Bowen et al (19) reported patients with recurrent bacterial infections associated with deficiency of neutrophil surface glycoproteins of 150,000 Mr and 180,000 M" respectively. Patient neutrophils studied by Bowen et al (19) failed to adhere to a variety of artificial substrates, and electron microscopy showed a failure to flatten and form fine pseudopods. Arnaout et al (15) reported a defect in neu trophil receptor-mediated phagocytosis of opsonized particles but normal neutrophil motility and chemotaxis; because of this latter fi nding, this patient was at first thought to differ from the others (but see below).
The Molecular Deficiency Defined
The Mr range of 110,000 to 180,000 of the missing surface glycoprotein was consistent with it being the 165,000-Mr IX subunit of Mac-I . Mac-l had been described in mouse and humans as an IX/3 complex with subunits of Mr 165,000 (oc) and 95,000 (/3) present on macrophagejmonocytes, neutrophi1s , and large granular lymphocytes (42 (20) , and Springer et al (3) reported that both the oc and /3 subunits of Mac-l (also designated Mol) were deficient on patient neutrophils. Anderson et al (2), Springer et al (3), and Arnaout et a1 (13) found that the LF A-I rx/3 complex, which has a /3 subunit identical to that of Mac-I, is also defi cient on patient neu trophils and lymphocytes. Springer et al (3, 9) also found that a third type of rx/3 complex, designated p 150,95, was defi cient on patient cells. Based on biosynthesis studies and on deficiency of all three rx subunits and the common /3 subunit, Springer et al proposed that the primary defect was in the f3 subunit, and that the f3 subunit was necessary for cell surface expression of the a subunits (3). Subsequent to these findings, 30 patients with recurring bacterial infections (including some described above in the section on early reports) were found to lack the Mac-l and LFA-l glycoproteins (4, 23, 2�28, 30-32, 44) ( Table I) .
Thus a group of patients having the same clinical syndrome and the same molecular defect were defined at the same time. We have previously referred to this syndrome as Mac-I, LFA-l-defi ciency disease (3, 4, 45); and others have referred to it as Mo I defi ciency (13) . Tn the interests of brevity and comprehensiveness, we now suggest the name "leukocyte adhesion defi ciency" (LAD).
The Mac-i, LFA-i, pi50,95 Glycoprotein Family Before further discussing the interesting clinical and functional defects in leukocyte adhesion deficiency, we discuss (a) the structure and function of the Mac-I, LFA-l glycoproteins, (b) the molecular basis and inheritance of the genetic defect, and (c) evidence for heterogeneity in the mutations affecting the common f3 subunit, which are of importance for under standing heterogeneity among patients.
The structure, cell distribution, and function of Mac-l and the two related glycoproteins that have identical 95,000-Mr f3 subunits are sum marized in Table 2 . Mac-l and LFA-l were defined fi rst in the mouse and then in humans. The molecules in both species are homologous and have such similar properties that they are discussed interchangeably (1 1, 42, 46, 47) . The distribution of Mac-I, LFA-l, and p1 50,95 is limited to white blood cells (42, 48; A. Bhan and T. A. Springer, unpublished) and hem atopoietic precursor cells (49, 50) . This is consistent with the fact that bone marrow transplantation can completely cure patients with leukocyte adhesion defi ciency (22) .
The Mac-I , LFA-I, and pI50,95 molecules are af3 complexes defi ned with MAbs specifi c for their aM, aL, and aX subunits, respectively (1 , 9, 51). Numerous MAbs have been obtained that are specific for each a subunit, as demonstrated by reactivity with the isolated subunits. Depend ing on the MAb being used, Mac-l may also be designated Mol, OKM1, 60.1 , or CDl l (51). The designations LFA-I and p1 50,95 are widely accepted. No a-subunit cross-reactive MAb or serum has thus far been identified. In contrast, MAbs specific for the f3 subunit do cross-react with all three af3 complexes (1).
The distinction among the three a subunits and the identity of the f3 subunits are supported by peptide mapping, amino acid sequencing, and physicochemical characteristics (1 , [52] [53] [54] LFA-l participates in lymphocyte and monocyte adhesion to cells (58) . It can mediate antigen-independent adhesion. LFA-l also appears to be required for T-Iymphocyte antigen-dependent adhesion to and killing of some target cells. Similarly, LFA-l has been demonstrated to be important in natural killing and antibody-dependent killing by K cells and gra nulocytes, and in T-Iymphocyte helper cell interactions. All LFA-I-depen dent functions require Mg+ 2 . Neutrophil adherence and aggregation (which are Mac-l dependent, see below) also require Mg+ 2 (59). Thus Mg+ 2 dependence is a common theme of functions mediated by the gly coprotein family.
While purified p150,95 has been shown to bind iC3b (57), the functional importance of p150,95 as a cell surface iC3b receptor has yet to be dem onstrated (60)'. p150,95 is important in adherence to surfaces (10), but its functional role is less well defined than that of Mac-I and LFA-l.
Biosynthesis of Mac-i, LFA-i, and pi50,95
Biosynthesis of these glycoproteins has been studied both in the mouse and in humans (1, 61); translation and glycosylation in vitro has been studied in the mouse (62) . Using cloned probes, researchers have defined the murine Mac-I a-subunit mRNA of 6 kilobases (63) and the human 13-subunit mRNA of 3.2 kilo bases (T. K. Kishimoto et aI, unpublished). The following model of biosynthesis has emerged ( Figure I ). Each of the three a subunits and the common 13 subunit is encoded by a separate mRNA. The subunits are synthesized as precursors that are cotranslationally gly cosylated with N-linked high mannose carbohydrate groups. After IY.-and f3-subunit association, which occurs 1�2 hours after synthesis, most of the high mannose groups are converted to complex-type carbohydrates in the Golgi apparatus, and the subunits increase slightly in Mr. The mature glycoproteins are then transported to the cell surface or to storage sites in intracellular secretory vesicles.
Intracellular Stores
In unstimulated blood granulocytes and monocytes, Mac-I and p150,95 are present in an intracellular, vesicular compartment as well as on the cell 
Molecular Deficiency and Severe and Moderate Phenotypes
Using MAbs specifi c for the three rx subunits and the common fJ subunit, researchers found all four subunits to be deficient in patient leukocytes (3, 4, 9). Thus, all three rx fJ complexes are defi cient. Patient granulocytes and monocytes are defi cient in intracellular stored pools and so is surface expression of the rxfJ complexes, as shown by SDS-PAGE of total cell lysates as well as by the lack of inflammatory mediator-induced up-regulation of Mac-l and p150,95 (4, 9, 17). Other leukocyte cell types are also defi cient, including peripheral blood lymphocytes and cultured cytolytic T-Iymphocytes, mitogen-stimulated T-Iymphocytes, and EBV transformed B-lymphocyte cell lines (3, 8, 13). We have examined ten patients with MAbs specific for all four subunits (4), and other labs have reported studies on MAbs specific for two of the ex subunits and/or the common fJ subunit (13, 20, 23, 27, 30, 32) . There is thus far no example of a selective deficiency in only one or two of the exfJ complexes; a defi ciency in all three appears to be a general fi nding. One important difference among patients is in the quantitative extent of deficiency. Among ten patients examined, we have found two phenotypes, which we designate "severe" and "moderate" deficiency (3, 4). As mea sured by immunofluorescence flow cytometry, and verified by radioim munoassay and immunoprecipitation, four severely deficient patients have essentially undetectable expression «0.3% of normal amounts) of all three rxfJ complexes on their granulocytes. Six moderately defi cient patients express 2.5 to 6% of all three rx fJ complexes. The important correlation between these phenotypes and the severity of clinical symptoms and defects in cell adhesion is discussed below.
Inheritance
Individuals who are clinically unaffected but appear to be heterozygous carriers of LAD have been ide n tified by expression of approximately 50% of normal amounts of the Mac-l ex subunit and the common fJ subunit on their f-Met-Leu-Phe-stimulated granulocytes (3, 4). In three families we have studied, all the clinically unaffected mothers and fathers and some of the siblings were found to be heterozygous. In one family spanning three generations, an affected son was born to heterozygous parents. The affec ted son married a heterozygote, and the couple bore an affected son and daughter and two heterozygous daughters. These fi ndings, together with an equal number of male and f emale patients (Table 1) , a frequent history of consanguineous marriages (4, 22, 23, 31, 39, 41) , and the presence in many families of both male and female patients (4, 26, 29, 32, 37, 38, 40) , strongly suggest that LAD is inherited as a recessive defect on an auto somal chromosome. In one family, X-linked inheritance was found (12, 13). However, no evidence for X-linked chromosome inactivation was reported for the mother, and thus further investigation is required before it can be concluded that LAD is a polygenic defect.
The Genetic Lesion
The molecular basis of the deficiency has thus far been studied via two methods: biosynthesis and human x mouse lymphocyte hybrids. Biosyn-thesis experiments have utilized EBV-transformed B-Iymphocyte and mitogen-stimulated T-Iymphocyte cell lines, which from healthy indi viduals synthesize the LFA-I IX subunit and the common p subunit and express the LFA-I IXP complex on the cell surface. Early studies showed that patient cell lines synthesized apparently normal LFA-I IX-subunit precursor, but the IXL precursor did not undergo carbohydrate processing, did not associate in an IXP complex, and neither subunit was expressed on the cell surface (3) (Figure 1) .
In human x mouse lymphocyte hybrids, human LF A-I ry. and p subunits from normal cells could associate with mouse LF A-I subunits to form interspecies hybrid IXP complexes (11). Surface expression of the IX but not the p subunit of patient cells was rescued by the formation of interspecies complexes. These findings show that the LF A-I IX subunit in genetically deficient cells is competent for surface expression in the presence of an appropriate mouse p subunit ; this suggests that the genetic lesion affects the p subunit. Thus the IX subunits must associate with the p subunit in an IXP complex in order to mature and be expressed in intracellular pools or on the cell surface (Figure 1) . The LFA-l IX subunit is degraded in the absence of the p subunit (3).
Recently, a rabbit anti-human p-subunit serum was developed that allowed p-subunit precursors in both healthy and defi cient cell lines to be immunoprecipitated and examined as to size in SDS-PAGE (T. K. Kishimoto, D. C. Anderson, and T. A. Springer, unpublished). These studies show that of four patients, all unrelated, one has an aberrantly large p precursor, two have p precursors of normal size, and one has no p precursor at all. Another group of four patients, all of whom are related to one another and have the moderate phenotype, have a p precursor of identically abnormal small size. Of ten relatives of the family with four patients, nine have been typed as heterozygote carriers and one as a noncarrier by quantity of surface expression (4). All nine heterozygotes show both a normal and an abnormally small p precursor; the noncarrier shows only the normal p precursor. These data provide conclusive evidence that the defect is in the p-subunit gene.
Differences in the p-subunit precursor between unrelated patients sug gest distinct mutations in the p-subunit gene. This means that while the moderate and severe phenotypes are useful in a broad sense for cate gorizing patients, some heterogeneity in the severity or spectrum of clinical symptoms within each category is to be expected. These biosynthesis studies provide no obvious molecular explanation for the moderate and severe phenotypes, because except for one patient the p precursor is syn thesized in amounts similar to that in normal cells. We hypothesize that mutant p subunits vary in their ability to complex with the IX subunits, and th i s determines the level of expressed afJ complex. In mouse x human lymphocyte hybrids, the fJ subunit and hence the genetic lesion has been mapped to chromosome 21 (11) . This is in agreement with autosomal inheritance.
Clinical and Histopathologic Features
The clinical and histopathologic features of 30 patients and 20 similar but unconfirmed patients with this disorder (Table 1) Table  3 (4).
Recurrent necrotic and indolent infections of soft tissues primarily involving skin, mucous membranes, and intestinal tract are the clinical hallmarks of LAD. Superfi cial infections of body surfaces may invade locally or systematically. Typical small, erythematous, nonpustular skin lesions often progress to large, well-demarcated, ulcerative craters, or "pyoderma gangrenosa" (4, 27, 29), which heal slowly or with dysplastic eschars. Staphylococcal or gram-negative enteric bacterial organisms may be cultured from such lesions for up to several weeks despite antimicrobial therapy. Fulminant progression of "gas gangrene" of soft tissues of a distal extremity in one patient prompted surgical amputation as a life saving measure (19) . Septicemia progressing from omphalitis associated with delayed umbilical cord severance has been observed in several infants (4, 22, 37). Perirectal abscess or cellulitis leading to peritonitis and/or septicemia has been reported in multiple patients (4, 15, 19, 37), and facial or deep neck cellulitis has been observed to progress from ulcerative mucous membrane lesions of the oral cavity (4, 19). Recurrent invasive candidal esophagitis and erosive gastritis were prominent clinical features in two patients (29, 38) . Three patients in the Texas series have developed acute appendicitis; in one case this was associated with a fatal necrotizing enterocolitis syndrome (4). Nearly fatal peritonitis resulting from a necrotic ileal ulcer occurred in one other patient (40) .
Recurrent otitis media occurs commonly, and progression to mastoiditis and facial nerve paralysis has been reported (4, 15, 19, 27, 37). Other common respiratory infections include severe bacterial (pseudomonal) laryngotracheitis (4, 12, 29), recurrent pneumonitis, or sinusitis (4, 19, 27) . Severe gingivitis and/or periodontitis is a major feature among all patients who survive infancy. Acute gingivitis has appeared in all cases with erup tion of the primary dentition. Subsequently, these patients develop charac teristic features of progressive generalized prepubescent periodontitis, including gingival proliferation, defective recessions, mobility, pathologic migration, and advanced alveolar bone loss associated with periodontal pocket formation and partial or total loss of both the deciduous and permanent dentitions (4, 64). The recurrent necrotic soft tissue infections observed in affected patients appear to reflect a profound impairment of leukocyte mobilization into extravascular inflammatory sites. Rebuck skin windows as well as biopsies of infected cutaneous, periodontal, umbilical cord, or other soft tissues demonstrate inflammatory infi ltrates totally devoid of neutrophilic gra nulocytes (4, 19, 34) . This histopathologic feature is particularly striking considering that marked peripheral blood granulocytosis (5-to 20-fold higher than normal) is a constant and characteristic feature of this disorder. Leukocyte transfusions result in the appearance of granulocytes and mon ocytes in Rebuck skin windows and in skin chambers (1 9; D. C. Anderson, unpublished) , and often are accompanied by a drop in the peripheral blood white count. Preferential localization of donor as opposed to host leukocytes (> 97% of donor origin) in an abscess has been found (1 9). Impaired healing of traumatic or surgical wounds observed in several of our patients represents a clinical feature of LAD not found in neutropenia syndromes or other disorders of granulocyte function (4, 19, 27, 35, 64) . Unusual paper-thin or dysplastic cutaneous scars characterized three pati ents of the Texas series as well as two patients described by Ross et al (27) . This may reflect the lack of monocyte infiltration and the lack of inflammatory contributions to "healing" such as the elaboration of angi ogenesis factors (4).
The wide spectrum of gram-positive or gram-negative bacterial and fungal infectious microorganisms (2, 4, 12, 15, 19, 22, 24, 27, 29-32, 34, 35, 37, 38, 40) is also characteristic of patients with primary neutropenia syndromes or individuals with a genetic defi ciency of neutrophil-specific granules. These other clinical models also demonstrate insufficient tissue leukocyte infi ltration. However, deep-seated granulomatous infections characteristic of chronic granulomatous disease and other examples of oxidative or nonoxidative intracellular killing deficits have not been observed.
Whether susceptibility to viral infection is increased in this disorder is uncertain. Most patients in the Texas series and several patients reported elsewhere have demonstrated normal and self-limiting courses of varicella or other viral respiratory infections. Five of ten patients in the Texas series demonstrated no untoward reactions to live viral vaccine administration. However, patient # 3 of the Texas series died of an overwhelming infection with picornavirus involving oral pharynax, glottis, trachea, and lungs; and three patients of the same series had one or more episodes of aseptic (presumably viral) meningitis (4).
The severity of clinical infectious complications among patients appears to be directly related to the degree of glycoprotein deficiency (Table 3) . In our series, two of four patients with "severe" deficiency died in infancy, and those surviving infancy have demonstrated a susceptibility to severe, life-threatening systemic infections (peritonitis, septicemia, pneumonitis, aseptic meningitis). In contrast, among six patients (five of whom are related) with "moderate" deficiency (mean age 21 years, range 9-38 years), life-threatening infections have been infrequently observed despite a rela tively prolonged survival. Patients within a kindred have similar survival periods (Table 1 ), e.g. three died in the study by Weening et al (30) at ages 22, 19, and 32 years (moderate disease); three died in their fi rst year in the studies by Hayward et al and Bissenden et al; and three in Niethammer's study died at 0, 1, and 3 years old (presumably severe disease). In some moderately affected patients, skin lesions may disappear after the fi rst few years of birth, recurring only with occasional infections. Severe gingivitis is always observed in these patients and may be the presenting symptom. Even patients with moderate phenotypes who appear relatively disease free may, however, rapidly develop infections with complications and die despite strenuous intervention. This is illustrated by the deaths at age 19 and 32 years of siblings of a moderately defi cient patient (29, 30) . Delayed umbilical cord separation occurs more frequently in patients with the severe rather than the moderate phenotype, but is not universally found even in the severe phenotype [Table 3 (28) ] ; since the length of time to separation is greatly affected by hygienic procedures, it is not a reliable indicator of the disease.
Functional Abnormalities
More profound abnormalities of tissue leukocyte infiltration and in vitro chemotaxis, hyperadherence, phagocytosis of iC3b-opsonized particles, and complement or antibody-dependent cytotoxicity were observed among severely as compared to moderately defi cient individuals in the Tcxas series (4). Some of the heterogeneous results between individual patients or kindreds may also reflect methodologic differences among reporting lab oratories (2, 4, 12, 15, 19,22,24,27, 29-32, 34, 35, 37, 38, 40) . However, as first observed by Crowley et al (12) and later among our patient popu lation (2, 4), abnormalities of granulocyte (and monocyte) adherence to substrates and adhesion-dependent functions including chemotaxis and aggregation have been observed among almost all patients studied. Chemotaxis appears to be affected because it requires adhesion. CR3-dependent binding and phagocytosis of iC3b-opsonized particles is defi cient, in agreement with the identity of the CR3 with Mac-l (55). Opsonized particles are phagocytosed poorly, and hence fail to trigger the respiratory burst (2, 5, 15, 22, 26, 29, 34, 39) . Abnormalities of granulocyte or mononuclear leukocyte antibody-dependent cellular cytotoxicity have also been observed in several patients (4, 7, 65). In contrast, adherence independent cellular functions including f-Met-Leu-Phe receptor-ligand binding, cell bipolarization, and oxidative metabolism or degranulation when mediated by soluble stimuli are generally normal (2, 4, 19, 22, 27,  31 ). Intracellular microbicidal activity (Staphylococcus aureus) in most, but not all, reported patients is relatively normal (2, 4, 19, 29, 65) ; this may reflect the presence of quantitatively and qualitatively normal IgG, Fc, CR-I, and other receptors on defi cient granulocytes (2--4, 66) .
The predominant occurrence of recurrent bacterial (as opposed to viral or fungal) infections in Mac-I-deficient patients implies that the functions of the granulocyte or monocyte are more profoundly affected than are lymphocyte functions. This might be because granulocytes and monocytes normally express Mac-I, LFA-I, and p150,95 while lymphocytes normally express only LFA-I (1, 67). Not unexpectedly, defi cits ofLFA-l-dependent lymphocyte functions have been observed in many patients. In other cases, LFA-l-dependent functions are nearly normal but are inhibited by much lower concentrations of monoclonal antibodies to LF A-I than for normal cells. T-Iymphocyte-mediated killing, proliferative responses, natural kill ing, and antibody-dependent killing by patient lymphocytes are deficient compared to adult controls (7, 8, 22, 23, 27, 34, 38, 65) . After primary mixed lymphocyte culture, lymphocytes in several studies demonstrated profoundly diminished cytotoxic and proliferative responses and inter feron production (8, 20, 23, 38) . However, after secondary and further stimulation, responses increased to nearly nonnal levels (8). This may be due to compensatory mechanisms, perhaps involving an increase in the affinity of the T-cell antigen receptor, and may account for relatively normal B-and T-Iymphocyte function observed in most cases. Delayed cutaneous hypersensitivity reactions are normal among most patients tested, and most individuals demonstrate normal specifi c antibody syn thesis (4, 19, 31 ). However, impaired T-Iymphocyte-dependent antibody responses in vivo (for example, to repeated vaccination with tetanus, diphtheria toxoids, and polio virus), and no in vivo or in vitro antibody production in response to infl uenzae virus were clearly docU1Jlented in one patient (25) . The deficits of in vivo lymphocyte responses may be found in only some of the severely deficient patients whose f3 subunit mutation is particularly deleterious to the LFA-I molecule.
Deficiency of Upregu/ation of Mac-J and pJ50,95: Relation to Clinical and Histopathologic Features Impaired granulocyte hyperadherence and mobility in this clinical disorder appears to be related to impaired mobilization by inflammatory mediators of intracellular stores of Mac-l and p150,95 to the cell surface. Whereas a 5-to 10-fold increase in Mac-1 and p150,95 surface expression is con sistently demonstrated when normal granulocytes are stimulated with chemotactic factors or PMA in vitro, little or no increase in these proteins is observed on patient granulocytes (3, 4, 17, 68 ). Other functions of patient cells are normally elicited by f-Met-Leu-Phe or PMA, including cell bipolarization, complement receptor-1 "upregulation," release of specific granule contents, and production of superoxide (4). These fi ndings suggest that normal granulocyte hyperadherence and aggregation is mediated by the increased surface expression of Mac-l and pI50,95. Thus, we propose that in vivo. chemoattractants diffusing from sites of inflammation into the circulation elicit enhanced cell surface Mac-l and pI50,95, which leads in turn to granulocyte and monocyte aggregation and adherence to endothelial cells at the inflammatory site. Adherence mediated by these glycoproteins may also be essential for granulocyte migration into extra vascular sites. The profound inability of patient granulocytes to migrate into inflammatory sites appears related to a lack of enhancement of cell adhesion to vascular endothelium. Several studies found patient gra nulocytes and monocytes to be defi cient in adherence to endothelial cells (21, 69 , but see 14) or to fi bronectin-coated substrates (14) .
Inhibition of Adherence-Dependent Functions by Anti-M ac-J M Abs
In recent studies, the defects in patient cells have been reproduced in normal cells by treating them with MAb (10, 20, 70) . Inhibitory effects of MAbs specific for individual 0: subunits indicate distinct adhesive con tributions of each o:f3 complex (10). Anti-o:M, o:X, and -f3 MAbs inhibit adherence of granulocytes both under baseline conditions and when increased surface expression of aM{3 and aX{3 complexes is stimulated by infl ammatory mediators. A higher percentage of cells adhere after stimulation; both stimulated and baseline adherence are almost completely inhibited by anti-{3-subunit and anti-Mac-lo:-subunit MAb. The general order of potency of inhibition is anti-f3 > anti-Mac-lo:» anti-plSO,9So: > anti-LFA-la, which reflects the relative amounts of each molecule expressed on granulocyte surfaces. Inhibition of directed migration by anti-{3, or anti-o:M MAbs is observed in subagarose (two-dimensional) but not Boyden chemotaxis assays. Inhibition is dependent upon a con tinuous cell exposure to anti-Mac-lo: or f3 during the assay, which suggests that recycled or new Mac-l is required for directed translocation. Phago cytosis of particles selectively opsonized with C3-derived ligands and bind ing of iC3b-opsonized sheep red blood cells are generally inhibitable by anti-aM MAbs but not by anti-{3. -aL, or -aX M A bs. These findings suggest the Mac-l molecule demonstrates "nonspecific" adhesive properties in addition to a specifi c capacity to recognize and bind iC3b. Notably, none of the anti-Mac-l MAbs demonstrate inhibitory effects in assays of adher ence-independent functions that are normal among genetically defi cient cell suspensions. These studies prove that the functional defi ciencies in patient cells are due to lack of the Mac-I, LFA-l, and p150,95 gly coproteins.
Therapy

BONE MARROW TRANSPLANTATION
Bone marrow transplantation with successful engraftment of donor cells completely restored leukocyte func tion and rendered unnecessary any further treatment in two patients (4, 44). In two other patients, successful engraftment was achieved, but recov ery did not occur either because of graft-versus-host disease or infectious complications. Transplantation is recommended for severely deficient pa tients because of the high incidence of death before the age of 2 (22; Table 1 ). Moderately deficient patients live longer but may also die from infections; the occurrence of deaths at the ages of 19, 22, and 32 (Table  1 ) and the absence of any known patients older than 38 years shows that survival through adolescence is no guarantee of a long life. Therapeutic guidelines for management of moderately defi cient patients are not well defi ned.
USE IN TRANSPLANTATION IN OTHER TYPES OF DISEASES OF LFA-\ MAB IN VIVO
HLA-mismatched bone marrow transplantation has proven suc cessful in many different diseases recently, in part because of depletion of donor T cells to prevent graft-versus-host disease. However, the incidence of donor rejection of the graft has become more troublesome. Fischer et al (44) observed that LFA-I-defi cient patients, none of whom mounted allogeneic mixed lymphocyte responses, did not reject grafts. Since (a) graft rejection can be mediated by both T and non-T cells, (b) LFA-l MAbs inhibit both T and natural killer immune functions in vitro (58) , and (c) LFA-I is not on hematopoietic stem cells (49, 50), Fischer et al treated graft recipients with 0.1 mg/kg anti-LFA-l a-subunit MAb from three days before to five days after transplantation. Recipients had a variety of inherited diseases such as Wiskott-Aldrich syndrome and osteo petrosis, and all received HLA-mismatched transplants. The use of LF A I MAb resulted in seven of seven successful engraftments, a dramatic improvement over the previous experience. Thus, the clinical experience with LAD and concepts based on the functional effects of LFA-l MAb in vitro have led to new treatment modalities in the therapy of other diseases.
GENE THERAPY
The identifi cation of the genetic lesion in LAD in the common f3 subunit of the Mac-I , LFA-l glycoprotein family predicts that introduction of a normal {3-subunit gene into hematopoietic cells should cure the disease. The mouse {3 subunit has been shown to complex with and rescue surface expression of the patient LF A-I IX subunit in pa tient x mouse lymphocyte hybrids (11). Recently, a eDNA clone for the {3 subunit was obtained (T. K. Kishimoto, T. Roberts, and T. A. Springer, unpublished) . Efforts are now being directed towards introducing (via retroviral vectors) the {3-subunit gene into bone marrow cells, with the goal of curing this disease through gene therapy.
Literature Cited
I. Sanchez-Madrid, F., Nagy, J., Robbins, E., Simon, P., Springer, T. 
